Pay vs Performance Disclosure - USD ($)

12 Months Ended

Dec. 31, 2025

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Pay vs Performance Disclosure

Pay vs Performance Disclosure, Table

Pay Versus Performance

The disclosure provided in this section is required by the SEC and does not necessarily align with the Company’s view of the relationship between its performance and the compensation of its Named Executive Officers. We believe our discussion in the “Compensation Discussion and Analysis” properly outlines how we view our executive compensation structure and how that aligns with the Company’s performance and objectives.

In accordance with Item 402(v) of Regulation S-K, the following table shows the total compensation for our Named Executive Officers for fiscal 2025, 2024, 2023, 2022 and 2021 as set forth in the Summary Compensation Table (the “SCT”) of this proxy statement and in the definitive proxy statement on Schedule 14A filed with the SEC on February 29, 2024, the “compensation actually paid,” as computed in accordance with Items 402(v) of Regulation S-K (the “CAP”), to our CEO, and, on an average basis, the compensation actually paid to our other Named Executive Officers (the “other NEOs”), our total shareholder return (“TSR”), the TSR of the Nasdaq Biotechnology Index, which constitutes the “Peer Group”, our net income, and our revenue, which is our company selected financial measure, all measures over the same time period.

For purposes of the chart below, Drs. Hsiao and Zerhouni and Messrs. Rubin and Logal are the other NEOs for fiscal 2025 2024, and 2023. Drs. Hsiao and Jon Cohen, the Company's former Senior Vice President who retired from the Company in 2022, and Messrs. Rubin and Logal are the other NEOs for fiscal 2022. Dr. Zerhouni's compensation is also taken into consideration in the compensation of our other NEOs with respect to a portion of fiscal 2022; and Drs. Hsiao and Cohen and Messrs. Rubin and Logal are the other NEOs for fiscal 2021.


	SCT TOTAL					AVG SCT TOTAL PAY		AVG CAP			Value of Initial $100 Investment Based on:(4)
YEAR(1)	PAY FOR CEO(2)		CAP to CEO(3)			FOR OTHER NEOS		TO OTHER NEOS			Company TSR		Peer Group TSR		Net Income(5)			Revenue(6)
2025		1,854,000		1,344,700			1,660,250		1,183,766			31.90		124.75		(225,680	)		606,879
2024		2,163,800		2,015,925			1,950,675		1,818,205			37.22		93.49		(53,224	)		713,142
2023		2,277,200		2,173,575			2,031,950		1,925,029			38.23		94.03		(188,863	)		863,495
2022		972,200		(1,247,785	)		803,001		(1,324,485	)		31.66		89.90		(328,405	)		1,004,196
2021		2,103,600		2,396,962			2,298,100		2,789,211			121.77		100.02		(30,143	)		1,774,718

(1)

For fiscal 2025, 2024, 2023, 2022 and 2021, Dr. Phillip Frost was the CEO.

(2)

These amounts reflect (i) the total compensation reported in the SCT for the applicable year in the case of our CEO; and (ii) the average of the total compensation reported in the SCT for the applicable year for our other NEOs. See the footnotes to the SCT for further detail regarding the amounts in this column.

(3)

Amounts reported in these columns represent CAP, which was computed by making certain adjustments to the amounts reported in the SCT for the applicable year. A reconciliation of the adjustments for our CEO and for the average of the other NEOs is set forth in the following tables, which describe the adjustments.

(4)

Reflects the cumulative TSR for the Company and the NASDAQ Biotechnology Index, which is the same industry index included in Part II, Item 5, “Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities,” furnished in the Company’s Annual Report on Form 10-K filed with the SEC on February 26, 2026, assuming, in each case, an initial investment of $100 on December 31, 2021.

(5)

Reflects “Net Income” in the Company’s consolidated statement of operations included in the Company’s Annual Report on Form 10-K for each of the years ended December 31, 2025, 2024, 2023, 2022 and 2021.

(6)

SEC rules require us to designate a “company-selected measure” that in our assessment represents the most important financial performance measure (that is not otherwise required to be disclosed in the table immediately above) used by the Company to link the CAP of our Named Executive Officers, for the most recently completed fiscal year, to our performance. We selected revenue as this measure for fiscal 2025, as reflected in the table above. This performance measure may not have been the most important financial performance measure for fiscal 2025, 2024, 2023, 2022 and 2021, and we may determine a different financial performance measure to be the most important financial performance measure in future years.


YEAR	SCT TOTAL PAY FOR CEO		MINUS EQUITY AWARD GRANT DATE FV REPORTED IN SCT FOR COVERED YEAR		PLUS YE FV OF EQUITY AWARDS GRANTED DURING THE COVERED YEAR THAT REMAIN OUTSTANDING AND UNVESTED		PLUS YOY CHANGE IN FV OF OUTSTANDING AND UNVESTED EQUITY AWARDS GRANTED IN PRIOR YEARS			PLUS YOY CHANGE IN FV AS OF THE VESTING DATE OF EQUITY AWARDS GRANTED IN PRIOR YEARS THAT VESTED DURING COVERED YEAR			CEO CAP
2025		1,854,000		400,000		315,000		(279,600	)		(144,700	)		1,344,700.0
2024		2,163,800		710,000		735,000		(125,000	)		(47,875	)		2,015,925.0
2023		2,277,200		824,000		712,000		(37,000	)		45,375			2,173,575.0
2022		972,200		—		—		(1,522,307	)		(697,678	)		(1,247,784.8	)
2021		2,103,600		1,132,000		1,116,026		390,724			(81,388	)		2,396,961.6


YEAR	SCT AVERAGE PAY FOR OTHER NEOs		MINUS EQUITY AWARD GRANT DATE FV REPORTED IN SCT FOR COVERED YEAR		PLUS YE FV OF EQUITY AWARDS GRANTED DURING THE COVERED YEAR THAT REMAIN OUTSTANDING AND UNVESTED		PLUS YOY CHANGE IN FV OF OUTSTANDING AND UNVESTED EQUITY AWARDS GRANTED IN PRIOR YEARS			PLUS YOY CHANGE IN FV AS OF THE VESTING DATE OF EQUITY AWARDS GRANTED IN PRIOR YEARS THAT VESTED DURING COVERED YEAR			AVG OTHER NEO CAP
2025		1,660,250		375,000		295,313		(262,125	)		(134,671	)		1,183,766
2024		1,950,675		665,625		689,063		(115,136	)		(40,771	)		1,818,205
2023		2,031,950		772,500		667,500		(28,298.14	)		(26,377.50	)		1,925,029
2022		803,001		8,801		8,091		(886,469.27	)		(1,240,307.41	)		(1,324,485	)
2021		2,298,100		1,202,750		1,116,026		541,633.61			36,202.20			2,789,211

The fair value of options was determined by using the Black-Scholes option pricing method.

Named Executive Officers, Footnote

Drs. Hsiao and Zerhouni and Messrs. Rubin and Logal are the other NEOs for fiscal 2025 2024, and 2023. Drs. Hsiao and Jon Cohen, the Company's former Senior Vice President who retired from the Company in 2022, and Messrs. Rubin and Logal are the other NEOs for fiscal 2022. Dr. Zerhouni's compensation is also taken into consideration in the compensation of our other NEOs with respect to a portion of fiscal 2022; and Drs. Hsiao and Cohen and Messrs. Rubin and Logal are the other NEOs for fiscal 2021.

(1)

For fiscal 2025, 2024, 2023, 2022 and 2021, Dr. Phillip Frost was the CEO.

Peer Group Issuers, Footnote

(4)

PEO Total Compensation Amount

$ 1,854,000

$ 2,163,800

$ 2,277,200

$ 972,200

$ 2,103,600

PEO Actually Paid Compensation Amount

$ 1,344,700

2,015,925

2,173,575

(1,247,784.8)

2,396,961.6

Adjustment To PEO Compensation, Footnote


YEAR	SCT TOTAL PAY FOR CEO		MINUS EQUITY AWARD GRANT DATE FV REPORTED IN SCT FOR COVERED YEAR		PLUS YE FV OF EQUITY AWARDS GRANTED DURING THE COVERED YEAR THAT REMAIN OUTSTANDING AND UNVESTED		PLUS YOY CHANGE IN FV OF OUTSTANDING AND UNVESTED EQUITY AWARDS GRANTED IN PRIOR YEARS			PLUS YOY CHANGE IN FV AS OF THE VESTING DATE OF EQUITY AWARDS GRANTED IN PRIOR YEARS THAT VESTED DURING COVERED YEAR			CEO CAP
2025		1,854,000		400,000		315,000		(279,600	)		(144,700	)		1,344,700.0
2024		2,163,800		710,000		735,000		(125,000	)		(47,875	)		2,015,925.0
2023		2,277,200		824,000		712,000		(37,000	)		45,375			2,173,575.0
2022		972,200		—		—		(1,522,307	)		(697,678	)		(1,247,784.8	)
2021		2,103,600		1,132,000		1,116,026		390,724			(81,388	)		2,396,961.6

Non-PEO NEO Average Total Compensation Amount

$ 1,660,250

1,950,675

2,031,950

803,001

2,298,100

Non-PEO NEO Average Compensation Actually Paid Amount

$ 1,183,766

1,818,205

1,925,029

(1,324,485)

2,789,211

Adjustment to Non-PEO NEO Compensation Footnote


YEAR	SCT AVERAGE PAY FOR OTHER NEOs		MINUS EQUITY AWARD GRANT DATE FV REPORTED IN SCT FOR COVERED YEAR		PLUS YE FV OF EQUITY AWARDS GRANTED DURING THE COVERED YEAR THAT REMAIN OUTSTANDING AND UNVESTED		PLUS YOY CHANGE IN FV OF OUTSTANDING AND UNVESTED EQUITY AWARDS GRANTED IN PRIOR YEARS			PLUS YOY CHANGE IN FV AS OF THE VESTING DATE OF EQUITY AWARDS GRANTED IN PRIOR YEARS THAT VESTED DURING COVERED YEAR			AVG OTHER NEO CAP
2025		1,660,250		375,000		295,313		(262,125	)		(134,671	)		1,183,766
2024		1,950,675		665,625		689,063		(115,136	)		(40,771	)		1,818,205
2023		2,031,950		772,500		667,500		(28,298.14	)		(26,377.50	)		1,925,029
2022		803,001		8,801		8,091		(886,469.27	)		(1,240,307.41	)		(1,324,485	)
2021		2,298,100		1,202,750		1,116,026		541,633.61			36,202.20			2,789,211

Compensation Actually Paid vs. Total Shareholder Return

Relationship Between “Compensation Actually Paid” and Performance Measures. The charts below compare the CAP to our CEO and the average CAP to our other NEOs with (i) our TSR, (ii) our net income, and (iii) revenue, which is our company selected measure, for fiscal 2025, 2024, 2023, 2022 and 2021. In addition, the charts below compare our TSR with our Peer Group TSR. We believe the CAP in each of the years reported above aligns with the performance metrics presented.

Non-Financial Performance Measures. The Company also considered the success, failure or progress made with respect to its R&D pipeline in setting pay-for performance compensation for fiscal 2025, as well as certain strategic transactions, including a sale of certain assets of BioReference.

Compensation Actually Paid vs. Net Income

Compensation Actually Paid vs. Company Selected Measure

Total Shareholder Return Vs Peer Group

Tabular List, Table

Financial Performance Measures. The most important financial performance measures used by the Company in setting pay-for-performance compensation for fiscal 2025 are set forth below, in no particular order.

-Adjusted Operating Income

-Revenue

-Relative Total Shareholder Return

Total Shareholder Return Amount

$ 31.9

37.22

38.23

31.66

121.77

Peer Group Total Shareholder Return Amount

124.75

93.49